Skip to main content

Table 1 Baseline and clinical characteristics of the study population

From: Long-term survival and BRCA status in male breast cancer: a retrospective single-center analysis

Characteristics Patients (n = 47)
Age at diagnosis 62.0 [55.0–72.0]
Age at diagnosis
  > 50 years 38 (80.9 %)
  ≤ 50 years 9 (19.1 %)
Body mass index 26.2 [24.2–28.9]
Family history 14 (29.7 %)
Smoker 10 (21.3 %)
Alcohol intake 10 (21.3 %)
Obesity 10 (21.3 %)
Side affected
 Left 29 (61.7 %)
 Right 17 (36.2 %)
 Both 1 (2.1 %)
Tumor stage
 I 16 (34.0 %)
 II 21 (44.7 %)
 III 6 (12.8 %)
 IV 1 (2.1 %)
 Unknown 3 (6.4 %)
 Histotype  
 Ductal 45 (95.8 %)
 Papillary 1 (2.1 %)
 Mixed 1 (2.1 %)
Hormone receptor positive
 ER 38/43 (88.4 %)
 PgR 35/43 (81.4 %)
 Both 34/43 (79.1 %)
 Unknown 4/47 (8.5 %)
ER+/PgR- 4/43 (9.3 %)
ER-/PgR+ 1/43 (2.3 %)
Hormone receptor negative 4/43 (9.3 %)
HER-2 positive 11/41 (26.8 %)
Unknown 6/47 (12.8 %)
Triple negative 3/43 (7.0 %)
Nodes status
 Positive 17/44 (38.6 %)
 Negative 27/44 (61.4 %)
 Unknown 3/47 (6.4 %)
Ki-67 high-level (cut off 20 %) 22/34 (64.7 %)
Unknown 13/47 (27.7 %)
Surgery
 Mastectomy 40 (85.1 %)
 Quadrantectomy 7 (14.9 %)
Radiotherapy 14 /43 (32.6 %) (4 unknown)
Chemotherapy 29/41 (70.7 %) (6 unknown)
Endocrine therapy 37/41 (90.2 %) (6 unknown)
Trastuzumab 7/42 (16.7 %) (5 unknown)
Relapse 9/40 (22.5 %) (6 unknown)
Other tumors 9 (19.1 %)
BRCA test
 No 30 (63.8 %)
 Yes 17 (36.2 %)
BRCA mutation
 BRCA 1 1 (5.9 %)
 BRCA 2 5 (29.4 %)
 Unknown variant sequence 1 (5.9 %)
 Negative 10 (58.8 %)
Death 7 (14.9 %)
 No BRCA test 4 (57.1 %)
 BRCA 1 1 (14.3 %)
 BRCA 2 2 (28.6 %)
Follow-up Median 2660 [1065–4452] days (7.3 years)
  1. Continuous variables are reported as median and interquartile range
  2. Abbreviations: ER estrogen receptor, PgR progesterone receptor